Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (51 quarters reported)
$267M in Q4 2013 → $178M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Innoviva Inc | 24.1% | Trimmed 11% | 1,890,604 | $42.9M |
| Ironwood Pharmaceuticals Inc | 21.7% | Unchanged | 9,188,635 | $38.7M |
| Amarin Corp PLC | 15.0% | Unchanged | 1,673,395 | $26.7M |
| Neurocrine Biosciences Inc | 11.0% | Unchanged | 116,533 | $19.6M |
| Cytokinetics Inc | 10.9% | Unchanged | 228,623 | $19.5M |
| LH Lantheus Hldgs Inc | 10.4% | Unchanged | 166,919 | $18.5M |
| Biohaven Ltd | 4.9% | Added 3.4% | 582,312 | $8.66M |
| Regeneron Pharmaceuticals | 1.5% | Unchanged | 4,190 | $2.61M |
| Vor Biopharma Inc | 0.3% | Unchanged | 25,399 | $468K |
| Biogen Inc | 0.1% | New | 950 | $205K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Innoviva Inc | Trimmed | −240,346 | −$5.46M | 24.1% |
| Biohaven Ltd | Added | +19,128 | +$285K | 4.9% |
| Biogen Inc | New | +950 | +$205K | 0.1% |
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Neurocrine Biosciences Inc | Trimmed | −186,618 | −$24.6M | 9.7% |
| Ironwood Pharmaceuticals Inc | Trimmed | −6,730,800 | −$23.6M | 20.5% |
| Innoviva Inc | Trimmed | −685,072 | −$16M | 31.5% |
| Cytokinetics Inc | Trimmed | −167,734 | −$11.1M | 9.6% |
| LH Lantheus Hldgs Inc | Trimmed | −14,531 | −$1.1M | 8.0% |
| Biohaven Ltd | Added | +50,000 | +$423K | 3.0% |
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cytokinetics Inc | Trimmed | −192,000 | −$12.2M | 11.3% |
| Amarin Corp PLC | Added | +430,868 | +$6.01M | 10.5% |
| Biohaven Ltd | New | +513,184 | +$5.79M | 2.6% |
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| LH Lantheus Hldgs Inc | Added | +85,199 | +$4.37M | 5.2% |
| Regeneron Pharmaceuticals | New | +4,190 | +$2.36M | 1.3% |
| Vor Biopharma Inc | New | +25,399 | +$1.24M | 0.7% |
| Vor Biopharma Inc | Exited | −508,016 | −$823K | — |
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Amarin Corp PLC | New | +1,242,527 | +$20.2M | 13.1% |
| Amarin Corp PLC | Exited | −24,850,623 | −$11.1M | — |
| Neurocrine Biosciences Inc | Trimmed | −5,965 | −$750K | 24.7% |
| Cytokinetics Inc | Trimmed | −11,643 | −$385K | 12.6% |
| Ironwood Pharmaceuticals Inc | Trimmed | −470,565 | −$337K | 7.4% |
| LH Lantheus Hldgs Inc | Trimmed | −3,749 | −$307K | 5.1% |
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Innoviva Inc | Trimmed | −4,460,978 | −$80.9M | 33.0% |
| Gilead Sciences Inc | Exited | −262,080 | −$24.2M | — |
| Cytokinetics Inc | Trimmed | −233,799 | −$9.4M | 15.6% |
| LH Lantheus Hldgs Inc | Added | +37,000 | +$3.61M | 6.3% |
| Vor Biopharma Inc | Trimmed | −109,984 | −$78.9K | 0.2% |
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Gilead Sciences Inc | Trimmed | −501,253 | −$46.3M | 7.5% |
| Neurocrine Biosciences Inc | Trimmed | −101,367 | −$13.8M | 13.1% |
| Cytokinetics Inc | Trimmed | −276,201 | −$13M | 12.1% |
| Biogen Inc | Exited | −26,950 | −$5.22M | — |
| LH Lantheus Hldgs Inc | Added | +37,000 | +$3.31M | 1.7% |
| Regulus Therapeutics Inc | Exited | −185,183 | −$291K | — |
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Biogen Inc | Trimmed | −616,050 | −$119M | 1.3% |
| Gilead Sciences Inc | Trimmed | −339,949 | −$28.5M | 15.9% |
| Biocryst Pharmaceuticals Inc | Exited | −1,094,168 | −$6.76M | — |
| LH Lantheus Hldgs Inc | New | +26,000 | +$2.85M | 0.7% |
Loading...
